Results 71 to 80 of about 4,911,014 (257)

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain

Journal of Pain Research, 2012
Joseph V Pergolizzi Jr,1,2 Mart van de Laar,3 Richard Langford,4 Hans-Ulrich Mellinghoff,5 Ignacio Morón Merchante,6 Srinivas Nalamachu,7,8 Joanne O'Brien,9 Serge Perrot,10 Robert B Raffa111Department of Medicine, Johns Hopkins ...
Pergolizzi Jr JV, van de Laar M, Langford R, Mellinghoff H-U, Morón Merchante I, Nalamachu S, O'Brien J, Perrot S, Raffa RB   +8 more
doaj  

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy

, 2016
Jennifer Hayes,1 Rosie Anderson,1 Jeffrey W Stephens1,2 1Department of Diabetes and Endocrinology, Morriston Hospital, ABM University NHS Trust, 2Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea, UK Abstract: Type 2 ...
Hayes J, Anderson R, Stephens JW
core  

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

FEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee, Mingming Tong, Anna L. Gloyn   +2 more
wiley   +1 more source

TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME. THE ROLE OF THE COMBINATION DRUGS

Рациональная фармакотерапия в кардиологии, 2015
Data about the current approach to the choice of dual antihypertensive combinations in various clinical situations for treatment of hypertension are presented.
A. M. Shilov, M. S. Dulaeva, A. O. Osia, A. S. Lishuta   +3 more
doaj   +1 more source

A comparative study on efficacy of fixed combination timolol/brinzolamide versus travoprost monotherapy in drug-naïve open-angle glaucoma patients

Therapeutic Advances in Ophthalmology, 2020
Background: Glaucoma is most common irreversible cause of blindness in India. First line management of open-angle glaucoma is either beta blockers or prostaglandin analogs monotherapy.
Alok Dixit, Atul Ashish, Reena Sharma
doaj   +1 more source

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review

, 2016
Rohit Kedia,1 Supriya Kulkarni,1 Meredith Ross,1 Vijay Shivaswamy1,2 1Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, 2VA Nebraska-Western Iowa Health Care System, Omaha, NE ...
Ross M, Shivaswamy V, Kedia R, Kulkarni S   +3 more
core  

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis

, 2021
DigitalBackground In randomised controlled trials, fixed-dose combination treatments (or polypills) have been shown to reduce a composite of cardiovascular disease outcomes in primary prevention.
Avezum, Alvaro, Sliwa, Karen, Joseph, Philip, Dagenais, Gilles R., Liu, Lisheng, Teo, Koon, Fuster, Valentin, Rodgers, Anthony, Yusuf, Salim, Bangdiwala, Shrikant I., Lopez-Jaramillo, Patricio, Polypill Trialists' Collaboration, Pais, Prem, Xavier, Denis, Diaz, Rafael, Bosch, Jackie, Gamra, Habib, Lonn, Eva, Gao, Peggy, Roshandel, Gholamreza, Prabhakaran, Dorairaj, Castellano, Jose Maria, Zhu, Jun, Huffman, Mark D., Dans, Antonio, Malekzadeh, Reza   +25 more
core   +1 more source

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source